Leteprinim

Last updated

Leteprinim
Leteprinim.svg
Clinical data
ATC code
  • none
Identifiers
  • 4-{{#parsoidfragment:2}}{[3-(6-oxo-3,6-dihydro-9H-purin-9-yl)propanoyl]amino}benzoic acid
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C15H13N5O4
Molar mass 327.300 g·mol−1
3D model (JSmol)
  • C1=CC(=CC=C1C(=O)O)NC(=O)CCN2C=NC3=C2NC=NC3=O
  • InChI=1S/C15H13N5O4/c21-11(19-10-3-1-9(2-4-10)15(23)24)5-6-20-8-18-12-13(20)16-7-17-14(12)22/h1-4,7-8H,5-6H2,(H,19,21)(H,23,24)(H,16,17,22)
  • Key:JMPOIZCOJJMTHI-UHFFFAOYSA-N
   (verify)

Leteprinim (Neotrofin, AIT-082) is a hypoxanthine derivative drug with neuroprotective and nootropic effects. [1] [2] [3] It stimulates release of nerve growth factors and enhances survival of neurons in the brain, [4] [5] [6] [7] [8] and is under development as a potential treatment for neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and stroke. [9] [10]

References

  1. ↑ Di Iorio P, Virgilio A, Giuliani P, Ballerini P, Vianale G, Middlemiss PJ, et al. (June 2001). "AIT-082 is neuroprotective against kainate-induced neuronal injury in rats". Experimental Neurology. 169 (2): 392–9. doi:10.1006/exnr.2001.7654. PMID   11358452. S2CID   43094767.
  2. ↑ Lahiri DK, Ge YW, Farlow MR (April 2000). "Effect of a memory-enhancing drug, AIT-082, on the level of synaptophysin". Annals of the New York Academy of Sciences. 903 (1): 387–93. Bibcode:2000NYASA.903..387L. doi:10.1111/j.1749-6632.2000.tb06390.x. PMID   10818529. S2CID   33710679.
  3. ↑ Yan R, Nguyen Q, Gonzaga J, Johnson M, Ritzmann RF, Taylor EM (April 2003). "Reversal of cycloheximide-induced memory disruption by AIT-082 (Neotrofin) is modulated by, but not dependent on, adrenal hormones". Psychopharmacology. 166 (4): 400–7. doi:10.1007/s00213-002-1350-5. PMID   12605287. S2CID   25028981.
  4. ↑ Rathbone MP, Middlemiss PJ, Crocker CE, Glasky MS, Juurlink BH, Ramirez JJ, et al. (August 1999). "AIT-082 as a potential neuroprotective and regenerative agent in stroke and central nervous system injury". Expert Opinion on Investigational Drugs. 8 (8): 1255–62. doi:10.1517/13543784.8.8.1255. PMID   15992149.
  5. ↑ Ramirez JJ, Parakh T, George MN, Freeman L, Thomas AA, White CC, et al. (2002). "The effects of Neotrofin on septodentate sprouting after unilateral entorhinal cortex lesions in rats". Restorative Neurology and Neuroscience. 20 (1–2): 51–9. PMID   12237496.
  6. ↑ Holmes M, Maysinger D, Foerster A, Pertens E, Barlas C, Diamond J (November 2003). "Neotrofin, a novel purine that induces NGF-dependent nociceptive nerve sprouting but not hyperalgesia in adult rat skin". Molecular and Cellular Neurosciences. 24 (3): 568–80. doi:10.1016/s1044-7431(03)00217-3. PMID   14664808. S2CID   13359687.
  7. ↑ Jiang S, Khan MI, Middlemiss PJ, Lu Y, Werstiuk ES, Crocker CE, et al. (2004). "AIT-082 and methylprednisolone singly, but not in combination, enhance functional and histological improvement after acute spinal cord injury in rats". International Journal of Immunopathology and Pharmacology. 17 (3): 353–66. doi:10.1177/039463200401700315. PMID   15461869. S2CID   26045848.
  8. ↑ Calcutt NA, Freshwater JD, Hauptmann N, Taylor EM, Mizisin AP (March 2006). "Protection of sensory function in diabetic rats by Neotrofin". European Journal of Pharmacology. 534 (1–3): 187–93. doi:10.1016/j.ejphar.2006.01.047. PMID   16507305.
  9. ↑ Potkin SG, Alva G, Keator D, Carreon D, Fleming K, Fallon JH (September 2002). "Brain metabolic effects of Neotrofin in patients with Alzheimer's disease". Brain Research. 951 (1): 87–95. doi:10.1016/s0006-8993(02)03140-2. PMID   12231461. S2CID   23021393.
  10. ↑ Johnston TH, Brotchie JM (July 2004). "Drugs in development for Parkinson's disease". Current Opinion in Investigational Drugs. 5 (7): 720–6. PMID   15298067.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.